Serum seladin-1 levels in diabetes mellitus and Alzheimer's disease patients

Basit Öğe Kaydı
dc.authoridOnmez, Attila/0000-0002-7188-7388
dc.contributor.authorOnmez, Attila
dc.contributor.authorAlpay, Merve
dc.contributor.authorTorun, Serkan
dc.contributor.authorSahin, I. Ethem
dc.contributor.authorOnec, Kursad
dc.contributor.authorDegirmenci, Yildiz
dc.date.accessioned2021-12-01T18:47:09Z
dc.date.available2021-12-01T18:47:09Z
dc.date.issued2020
dc.department[Belirlenecek]en_US
dc.description.abstractBackground Diabetes mellitus (DM) has been shown to increase the risk of Alzheimer's disease (AD). Downregulation of selective Alzheimer's disease indicator-1 (seladin-1) occurs in the cerebral regions affected by AD. However, inconsistent results have been reported for the relationship between seladin-1 levels and AD. The effect of DM on serum seladin-1 levels in AD is unknown. The present study is aimed to investigate serum seladin-1 levels in diabetic and non-diabetic patients with AD. Methods Forty-six patients with AD and 25 healthy volunteers over 65 years of age were included in this study. The patients were divided into three groups-those with AD only, those with DM and AD, and control groups. Demographic characteristics and serum seladin-1 levels were compared among the groups. Results There was no statistically significant difference in seladin-1 levels in the AD only group compared to the control group (p = 0.376). However, seladin-1 levels were significantly lower in the DM and AD group compared to the AD only and control groups (p = 0.002, p = 0.001; respectively). Negative correlations were present between seladin-1 and fasting glucose, postprandial glucose, HbA1c, and insulin (p < 0.05; all). Conclusion Decreased serum seladin-1 values in the presence of DM and inverse correlations with diabetic parameters in patients with AD, together with a non-significant difference from the control group, suggests that seladin-1 may be altered only in the presence of DM in patients with AD. Lower serum seladin-1 levels may also play a role in the pathogenesis of AD in patients with DM.en_US
dc.identifier.doi10.1007/s13760-020-01393-4
dc.identifier.endpage1404en_US
dc.identifier.issn0300-9009
dc.identifier.issn2240-2993
dc.identifier.issue6en_US
dc.identifier.pmid32506354en_US
dc.identifier.scopus2-s2.0-85085994149en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1399en_US
dc.identifier.urihttps://doi.org/10.1007/s13760-020-01393-4
dc.identifier.urihttps://hdl.handle.net/20.500.12684/10168
dc.identifier.volume120en_US
dc.identifier.wosWOS:000538345300002en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofActa Neurologica Belgicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDiabetes mellitusen_US
dc.subjectAlzheimer's diseaseen_US
dc.subjectDHCR24en_US
dc.subjectSeladin-1en_US
dc.subjectCholesterol synthesisen_US
dc.subjectRisken_US
dc.subjectInsulinen_US
dc.subjectExpressionen_US
dc.subjectDementiaen_US
dc.subjectGeneen_US
dc.subjectSystemen_US
dc.titleSerum seladin-1 levels in diabetes mellitus and Alzheimer's disease patientsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
10168.pdf
Boyut:
516.1 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu